Table 4.
Characteristics of the POPVIH65 Population After Matching Based on the Propensity Score Evaluating the Cost of DDIs (n = 3058)
| Baseline Characteristics | Patients Without DDI (n = 1529) | Patients With ≥1 DDI (n = 1529) | Standardized Difference, % |
|---|---|---|---|
| Male, No. (%) | 1142 (75) | 1130 (74) | 1.8 |
| Age, mean ± SD, y | 71.5 ± 5.1 | 71.1 ± 4.9 | 8.0 |
| HIV duration,a median [IQR], y | 16.2 [9.6–20.3] | 16.3 [9.9–20.9] | 2.8 |
| Diagnosis in 2016, No. (%) | 29 (2) | 18 (1) | 5.9 |
| 1 mo–10 y, No. (%) | 369 (24) | 392 (26) | 3.5 |
| 11–20 y, No. (%) | 714 (47) | 641 (42) | 9.6 |
| >20 y, No. (%) | 417 (27) | 478 (31) | 8.8 |
| Geographic repartition, No. (%) | |||
| Ile-de-France | 536 (35) | 539 (35) | 0.4 |
| Occitanie and Provence-Alpes-Côte D’Azur | 274 (18) | 269 (18) | 0.9 |
| Others regions | 719 (47) | 721 (47) | 0.3 |
| Concomitant diseases (non-HIV),b median [IQR] | 3 [1–4] | 3 [1–4] | 1.8 |
| Main concomitant diseases, No. (%) | |||
| Cardiovascular disease | 1068 (70) | 1043 (68) | 3.5 |
| Dyslipidemia | 708 (46) | 702 (46) | 0.8 |
| Anxiety, sleep disorders | 435 (28) | 416 (27) | 2.8 |
| Diabetes | 334 (22) | 337 (22) | 0.5 |
| Cancer | 198 (12) | 194 (13) | 1.0 |
| Hospitalizations during 2015, median [IQR] | 3 [0–8] | 3 [1–9] | 8.8 |
Abbreviations: ARV, antiretroviral; DDI, drug–drug interaction; IQR, interquartile range.
aHIV duration estimated from the date of the first long-term illness exemption related to HIV.
bTotal number of different diseases (HIV excluded). For more details about the determination of concomitant diseases, see the Appendix.